A new phototherapy regimen during winter as an add-on therapy, coupled with oral vitamin D supplementation, for the long-term control of atopic dermatitis: study protocol for a multicentre, randomized, crossover, pragmatic trial - the PRADA trial.
Administration, Cutaneous
Administration, Oral
Anti-Inflammatory Agents
/ administration & dosage
Cholecalciferol
/ administration & dosage
Combined Modality Therapy
Cross-Over Studies
Dermatitis, Atopic
/ diagnosis
Dietary Supplements
/ adverse effects
Double-Blind Method
France
Humans
Multicenter Studies as Topic
Pragmatic Clinical Trials as Topic
Seasons
Time Factors
Treatment Outcome
Ultraviolet Therapy
/ adverse effects
Atopic dermatitis
add-on therapy
long-term control
phototherapy
pragmatic trial
vitamin D
Journal
Trials
ISSN: 1745-6215
Titre abrégé: Trials
Pays: England
ID NLM: 101263253
Informations de publication
Date de publication:
25 Mar 2019
25 Mar 2019
Historique:
received:
04
05
2018
accepted:
01
03
2019
entrez:
27
3
2019
pubmed:
27
3
2019
medline:
4
9
2019
Statut:
epublish
Résumé
Atopic dermatitis is a highly prevalent, chronic, relapsing disease in both adults and children. On the severity spectrum, lower-end patients benefit from small amounts of topical anti-inflammatory treatments (TAT), whereas higher-end patients need systemic immunosuppressants; in-between patients are treated with TAT and phototherapy. The major therapeutic challenge in this population is the long-term control of disease activity, and the current TAT-based pro-active strategy does not meet all their needs. Immunosuppressants are used as long-term control add-on treatments, but they are restricted to the most severely affected patients because of safety concerns. In addition, neither immunosuppressants nor other strategies have been properly evaluated in the long term despite long-term control having been acknowledged as one of the most important core outcome domains to be targeted in atopic dermatitis trials. Safe add-on therapies, rigorously evaluated for long-term control of the disease, are therefore needed. Phototherapy and vitamin D supplementation are both good candidates. This is a multicenter, national, randomized, superiority, crossover trial testing add-on phototherapy (one winter under spaced sessions of phototherapy and one winter under observation) among subjects receiving standard care (i.e., TAT). On the same population, we will test the long-term control provided by oral supplementation of vitamin D versus placebo in a randomized, superiority, double-blind, parallel-group trial. The primary outcomes are (1) repeat measures of the PO-SCORAD severity score over 1 year and (2) cumulate consumption of TAT (number of tubes) during the winter. They will be tested following a hierarchical testing procedure. The secondary outcomes will be measures repeated over 2 years of investigator-based severity scores, patient-reported severity and quality of life scores, serum vitamin D levels, weeks during which the disease is well-controlled, inter-visit cumulate consumption of TAT, and synthetic patient-reported satisfaction at the end of each winter. This study includes two separate 2-year pragmatic trials designed to evaluate the efficacy of vitamin D supplementation and pro-active phototherapy for primary care atopic dermatitis patients receiving TAT on long-term control of disease activity. The experimental design enables the study of both interventions and exploration of the interaction between vitamin D and phototherapy. A pragmatic trial is particularly suited to the assessment of long-term control. This study explores the possibility of new and safe therapeutic strategies for the control of long-term atopic dermatitis, and is an example of efficacy research that is unlikely to be sponsored by industrialists. A potentially effective low-cost therapeutic strategy for long-term control is essential for patients and public health. ClinicalTrials.gov Identifier: NCT02537509 , first received: 1 September 2015.
Sections du résumé
BACKGROUND
BACKGROUND
Atopic dermatitis is a highly prevalent, chronic, relapsing disease in both adults and children. On the severity spectrum, lower-end patients benefit from small amounts of topical anti-inflammatory treatments (TAT), whereas higher-end patients need systemic immunosuppressants; in-between patients are treated with TAT and phototherapy. The major therapeutic challenge in this population is the long-term control of disease activity, and the current TAT-based pro-active strategy does not meet all their needs. Immunosuppressants are used as long-term control add-on treatments, but they are restricted to the most severely affected patients because of safety concerns. In addition, neither immunosuppressants nor other strategies have been properly evaluated in the long term despite long-term control having been acknowledged as one of the most important core outcome domains to be targeted in atopic dermatitis trials. Safe add-on therapies, rigorously evaluated for long-term control of the disease, are therefore needed. Phototherapy and vitamin D supplementation are both good candidates.
METHODS
METHODS
This is a multicenter, national, randomized, superiority, crossover trial testing add-on phototherapy (one winter under spaced sessions of phototherapy and one winter under observation) among subjects receiving standard care (i.e., TAT). On the same population, we will test the long-term control provided by oral supplementation of vitamin D versus placebo in a randomized, superiority, double-blind, parallel-group trial. The primary outcomes are (1) repeat measures of the PO-SCORAD severity score over 1 year and (2) cumulate consumption of TAT (number of tubes) during the winter. They will be tested following a hierarchical testing procedure. The secondary outcomes will be measures repeated over 2 years of investigator-based severity scores, patient-reported severity and quality of life scores, serum vitamin D levels, weeks during which the disease is well-controlled, inter-visit cumulate consumption of TAT, and synthetic patient-reported satisfaction at the end of each winter.
DISCUSSION
CONCLUSIONS
This study includes two separate 2-year pragmatic trials designed to evaluate the efficacy of vitamin D supplementation and pro-active phototherapy for primary care atopic dermatitis patients receiving TAT on long-term control of disease activity. The experimental design enables the study of both interventions and exploration of the interaction between vitamin D and phototherapy. A pragmatic trial is particularly suited to the assessment of long-term control. This study explores the possibility of new and safe therapeutic strategies for the control of long-term atopic dermatitis, and is an example of efficacy research that is unlikely to be sponsored by industrialists. A potentially effective low-cost therapeutic strategy for long-term control is essential for patients and public health.
TRIAL REGISTRATION
BACKGROUND
ClinicalTrials.gov Identifier: NCT02537509 , first received: 1 September 2015.
Identifiants
pubmed: 30909923
doi: 10.1186/s13063-019-3276-9
pii: 10.1186/s13063-019-3276-9
pmc: PMC6434814
doi:
Substances chimiques
Anti-Inflammatory Agents
0
Cholecalciferol
1C6V77QF41
Banques de données
ClinicalTrials.gov
['NCT02537509']
Types de publication
Clinical Trial Protocol
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
184Références
Annu Rev Public Health. 2000;21:193-221
pubmed: 10884952
Health Technol Assess. 2000;4(37):1-191
pubmed: 11134919
BMJ. 2003 Jun 21;326(7403):1367
pubmed: 12816824
Ann Epidemiol. 2004 Apr;14(4):296-303
pubmed: 15066610
N Engl J Med. 2008 Apr 3;358(14):1483-94
pubmed: 18385500
J Invest Dermatol. 2008 Dec;128(12):2880-7
pubmed: 18580964
Allergy. 2008 Jul;63(7):742-50
pubmed: 18592619
J Dermatol Sci. 2009 May;54(2):76-87
pubmed: 19303745
J Clin Epidemiol. 2009 May;62(5):464-75
pubmed: 19348971
CMAJ. 2009 May 12;180(10):1001-3
pubmed: 19372437
J Invest Dermatol. 2011 Jan;131(1):67-73
pubmed: 20739951
Br J Dermatol. 2011 Feb;164(2):415-28
pubmed: 20819086
Br J Dermatol. 2011 May;164(5):1078-82
pubmed: 21087229
N Engl J Med. 2011 May 5;364(18):1685-7
pubmed: 21542739
N Engl J Med. 2011 May 5;364(18):1695-707
pubmed: 21542741
Allergy. 2012 Mar;67(3):296-301
pubmed: 22171613
PLoS One. 2012;7(7):e39803
pubmed: 22808063
J Allergy Clin Immunol. 2012 Oct;130(4):925-31.e4
pubmed: 22947344
Pediatr Dermatol. 2013 May-Jun;30(3):359-63
pubmed: 23289912
Arch Dermatol Res. 2014 Apr;306(3):279-86
pubmed: 23982630
J Allergy Clin Immunol. 2013 Nov;132(5):1132-8
pubmed: 24094544
Br J Dermatol. 2014 Mar;170(3):501-13
pubmed: 24116934
J Stat Softw. 2013 Sep;54(10):
pubmed: 24403868
Allergy. 2014 Jan;69(1):3-16
pubmed: 24417229
J Allergy Clin Immunol. 2014 Jun;133(6):1615-25.e1
pubmed: 24655575
Ann Dermatol Venereol. 2014 Apr;141(4):265-71
pubmed: 24703640
Int J Epidemiol. 2014 Oct;43(5):1645-55
pubmed: 24756878
J Am Acad Dermatol. 2014 Aug;71(2):327-49
pubmed: 24813298
Br J Dermatol. 2014 Dec;171(6):1318-25
pubmed: 24980543
Ann Dermatol. 2015 Feb;27(1):10-4
pubmed: 25673925
Lancet. 2016 Mar 12;387(10023):1109-1122
pubmed: 26377142
J Am Acad Dermatol. 2016 Oct;75(4):681-687.e11
pubmed: 27544489
Nutrients. 2016 Dec 03;8(12):
pubmed: 27918470
J Invest Dermatol. 2017 Jun;137(6):1380-1384
pubmed: 28202402
Allergy. 2018 Jun;73(6):1284-1293
pubmed: 29319189
N Engl J Med. 1997 Jan 23;336(4):309-15
pubmed: 8995096
J Allergy Clin Immunol. 1999 Jan;103(1 Pt 1):125-38
pubmed: 9893196